DiagnoCure, Lab21 Ink UK Sales Pact | GenomeWeb

NEW YORK (GenomeWeb News) - DiagnoCure said today that Lab21 will sell its colorectal cancer staging test in the UK and Ireland.

Under the exclusive agreement, Lab21 will promote and sell the Previstage GCC Colorectal Cancer Staging Test in the two countries as part of its oncology testing services. DiagnoCure said that it will process the patient samples in its clinical lab in the US.

The company said that around 9,600 people in the UK could benefit from using the test for planning treatment staging each year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.